NeuroSense Therapeutics Ltd. has announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in patients with Amyotrophic Lateral Sclerosis (ALS). The analysis revealed a statistically significant effect at 18 months, with a p-value of 0.03, as demonstrated by the NfL-adjusted MMRM analysis. Participants who received PrimeC from the onset of the study exhibited a 28% relative difference in the decline of the ALS Functional Rating Scale-Revised compared to those who started with a placebo and were administered PrimeC after six months. The data suggests the clinical importance of early initiation of PrimeC in disease progression. The results were adjusted for baseline neurofilament light levels, confirming consistent benefits after considering patient variability. This report indicates PrimeC's potential as a disease-modifying therapy for ALS, though it does not specify if or when these results will be presented at future events.